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Table 2
MV analysis of RDs vs. URDs pain/MTC. URDs OR ¼ 1.0
OR RDs
BM
p-value OR RDs
PBSC
p-value
Donation pain 2-4 1.20 0.352 1.63 <0.001
Donation pain 3-4 11.00 <0.001
Donation MTC 2-4 1.32 0.230 2.38 <0.001
Recovery to baseline
pain 2-4
1.18 0.535 0.79 0.031
Recovery to baseline
MTC 2-4
1.15 0.672 0.68 0.001
Table 2
Multivariate analysis of BM donors by collection center experience: Odds
Ratio (p-value).
BM
Collection
frequency
Grade 2-4
pain,
collection
Grade 2-4
symptoms,
collection
Grade 2-4
pain, 1-wk
post-
collection
Grade 2-4
symptoms,
1-wk post-
collection
>1 every 2m 1.0 1.0 1.0 1.0
1 every 2m 1.25 (<0.01) 1.41 (0.16) 1.55 (0.07) 2.09 (<0.01)
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of increased pain/symptoms was associated with centers
that performed smaller number of PBSC collections. For BM
donors, Black males reported signiﬁcantly higher levels of
pain after the procedure (Table 1). No differences were noted
by SES groups after BM collection. Different levels of BM
collection experience were tested to determine cutpoints;
the optimal cutpoint was noted to be 1 or fewer collections
every 2 months. BM donors from centers collecting less than
this frequency weremore likely to have persistent symptoms
(Table 2).
Conclusions: In general, race and SES have a minimal effect
on symptoms associated with donation. Of note, however,
centers performing 1 BM collection every 2 months have
more symptoms reported after BM collection, and ap-
proaches should be developed by low volume centers to
address this issue.
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Baseline and 1 year post-donation pain/MTC, and rates of recovery to
baseline levels
BM PBSC
URDs RDs p-
value
URDs RDs p-
value
Baseline skeletal
pain grade 2-4
0.46% 2.42% 0.039 0.61% 8.38% <0.001
Baseline skeletal
pain grade 3-4
0% 0% 1.000 0% 1.85% <0.001
Baseline max MTC 2-4 0.82% 0.81% 1.000 0.51% 2.57% <0.001
1yr skeletal pain 2-4 5.00% 10.64% 0.033 5.37% 14.27% <0.001
1yr MTC 2-4 4.61% 7.45% 0.211 3.79% 6.04% 0.012
% back to baseline
pain at 1 yr
77.11% 78.72% 0.795 78.32% 68.51% <0.001
% back to baseline
MTC at 1 yr
84.61% 87.10% 0.646 88.22% 83.31% <0.001Program, Minneapolis, MN; 6University of Pittsburgh,
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Prospective data regarding donation related toxicities in
related donors (RDs) of bone marrow (BM) and peripheral
blood stem cells (PBSC) are limited. To address this, the
NHLBI-funded Related Donor Safety Study (RDSafe;
NCT00948636) prospectively enrolled adult RDs between
2010 and 2013 at 54 transplant centers in the United States.
RDswere assessed for baseline health status and followed for
1 year after donation, collecting detailed information on
adverse events, pain levels and 10 donation-relatedmodiﬁed
NCI-CTC symptoms (MTC). A concurrently enrolled cohort of
NMDP unrelated donors (URDs) was assessed as a compar-
ator. This report compares baseline, donation, and 1 year
post-donation pain/MTC for RDs aged 18-60: 124 BM (38
centers, med age 33, 48% female) and 919 PBSC (42 centers,
med age 49, 44% female) to URDs: 1098 BM (18 centers, med
age 31, 42% female) and 3119 PBSC (20 centers, med age 31,
40% female).
Results: RDs of PBSC had higher levels of baseline grade 2-4
pain and MTC compared to URDs; RDs of BM had higher
baseline levels of pain, but not MTC (Table 1). Multivariable
analysis (Table 2) showed similar donation-related pain
and MTC rates of recovery for RDs and URDs of BM. In
contrast, RDs of PBSC had signiﬁcant increases in risk ofFigure 1. Skeletal Pain experienced by PBSC donor, by unrelated vs related, at
baseline, donation, and 1 year post-donation. (Skeletal pain represents pain in
at least one of the following sites: back, bone, headache, hip, limb, joint, and
neck.) The severity of skeletal pain is deﬁned as the maximum grade among
these pain sites.
Figure 2. Highest Toxicity Level Across All Body Symptoms (fever in the
absence of signs of infection. fatigue, skin rash, local reactions, nausea, vom-
iting, anorexia, insomnia, dizziness, and syncope) experienced by PBSC donors,
by unrelated vs. related donors, at baseline, donation, and 1 year post-
donation.
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4 MTC (Table 2) compared to URDs of PBSC. In addition, RDs
of PBSC were less likely than URDs of PBSC to return to
baseline levels of pain and MTC at 1 year. Although only a
small fraction of both URDs and RDs reported grade 2-4
pain/MTC 1 year post-donation (Table 1), RDs were 2-3
times more likely to report pain/MTC at 1 year than URDs.
Conclusions: RDs of PBSC have more baseline and donation-
related pain/MTC and less complete 1 year recovery than
URDs. Ongoing analysis of baseline health status of RDs on
the RDSafe trial is underway to further deﬁne differences
between RDs/URDs that could account for these higher levels
of pain/MTC.Fig. 1. CD8 cell dose and overall survival.21
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Peripheral blood stem cells (PBSC) are the major source for
allogeneic stem cell transplantations. It has been shown that
treatment with 7.5 mg/kg G-CSF for 5 days is sufﬁcient to
mobilize and collect required CD34+ cells for transplantation.
However, uncertainty remains in 0.5e5.0% of all donors
regarding insufﬁcient mobilization. In this retrospective
analysis we evaluated 5691 allogeneic stem cell mobilization
regimens (72% male vs. 28% female donors) from two major
collection centers focusing on donor risk factors for poor
mobilization. According to our historical reciprocal weight
and BMI-adapted mobilization protocol low weight/low BMI
donors received > 8.3mg/kg/d for 4 days, whereas overweight
donors received <7.5 mg/kg. At day 5 all donors received
526mg G-CSF 2 hours before apheresis. In total, a mean G-CSF-
dosis of 8.9  1.0mg/kg/d for 5 days has been utilized (min
4.5mg/kg/d e max. 15.9mg/kg/d). Mean CD34+ cell concentra-
tion of 95 49/ml could be achieved in the peripheral blood at
day 5 before starting apheresis. This enabled us to collect amean of 9.7  8.0 CD34+ cells/kg body weight recipient cor-
responding to 658  252 million total CD34+ cells in the
product. In 96.3% of all cases one single apheresis was sufﬁ-
cient to collect the requested amount of CD34+ cells. Using
logistic regression analysis we deﬁned female sex, low BMI
and low platelet (PLT) count at baseline as strongest risk fac-
tors for poor mobilization. Low white blood cell (WBC) con-
centration, low hematocrit and G-CSF-doses < 9mg/kg/d were
also signiﬁcantly associated with poor mobilization. Using the
strongest numeric predictors (BMI, PLT) we employed STEPP-
analysis to establish a statistically signiﬁcant cross table risk
score, that allows prediction of CD34+ cells in the peripheral
blood at day 5 according to baseline PLT and BMI. From lowest
cumulative risk score 2 (PLT>290; BMI>34.5) to highest risk
score 6 (PLT<170; BMI<20.7) differences between all risk
scoreswere highly signiﬁcant. Interestingly, subgroup analysis
demonstrated that female but not male donors with poor risk
score that received > 9mg/kg/d G-CSF could improve signiﬁ-
cantly mobilization outcome without further side effects.
Thus, overall results demonstrated that weight adapted G-CSF
dosage for allogeneic donor treatment may improve mobili-
zation outcome, i.e. in poor risk prospect female donors with
low BMI and low PLT at baseline. Further genetic analysis may
identify factors responsible for mobilization outcome.22
A Survival Beneﬁt for Reduced Intensity Allogeneic
Transplants from Young Unrelated Donors Compared to
Older Sibling Donors Depends on the Graft CD8 T-Cell
Content
Ran Reshef 1, Austin P. Huffman 1, Amy Gao 1, Mary Sell 2,
Marlise R. Luskin 1, Selina Luger 1, Alison Loren 1,
Elizabeth O. Hexner 1, Sunita D. Nasta 1, Noelle V. Frey 1,
Saar Gill 1, James Mangan 1, Lee P. Richman 3,
Taku Kambayashi 2, Edward A. Stadtmauer 1,
Robert H. Vonderheide 3, Rosemarie Mick 4, David L. Porter 1.
1 Blood and Marrow Transplantation Program, Abramson
Cancer Center, Perelman School of Medicine at the University of
Pennsylvania, Philadelphia, PA; 2 Pathology and Laboratory
Medicine, Perelman School of Medicine at the University of
Pennsylvania, Philadelphia, PA; 3 Abramson Family Cancer
Research Institute, Perelman School of Medicine, University of
Pennsylvania, Philadelphia, PA; 4 Biostatistics and
Epidemiology, Perelman School of Medicine at the University of
Pennsylvania, Philadelphia, PA
Background: Younger donor age is associated with better
survival in unrelated donor bone marrow transplants, but
young unrelated donors have not shown an overall survival
